K T500mg/5ml
Type:100ml bot
Generic Name:Potassium Chloride
Manufacturer:Jayson Pharmaceuticals Ltd.
Price:৳30.09
Indication
Hypokalemia, Electrolyte replenisher
Administration
Should be taken with food.
Adult Dose
Oral Prophylaxis of hypokalaemia and mild K deficiency; Hypokalaemia Adult: Prevention of hypokalaemia: 20 mEq daily. Treatment of hypokalaemia 40-100 mEq/day bid-qid. Give in divided doses if >20 mEq/day. Intravenous Severe acute hypokalaemia Adult: If serum potassium level >2.5 mEq/L, give at a rate not exceeding 10 mEq/hr in a concentration of up to 40 mEq/L. Max dose: 200 mEq/24 hr. If serum potassium level <2 mEq/L, may infuse at a rate of up to 40 mEq/hr. Continuous cardiac monitoring is essential. Max dose: 400 mEq/24 hr. Max Dosage: 2-3 mmol potassium/kg body wt in 24 hrs.
Child Dose
Hypokalemia 0.5-2 mEq/kg PO q12hr Monitor closely: 0.5 mEq/kg/hr IV for 1-2 hr
Contraindication
Hyperchloraemia, severe renal or adrenal insufficiency.
Mode of Action
Potassium chloride is a major cation of the intracellular fluid. It plays an active role in the conduction of nerve impulses in the heart, brain and skeletal muscle; contraction of cardiac skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism and gastric secretion.
Precaution
Renal or adrenocortical insufficiency; cardiac disease; acute dehydration; extensive tissue destruction. Pregnancy. Ensure adequate urine output; monitor plasma-potassium and other electrolyte concentrations. Discontinue treatment if severe nausea, vomiting or abdominal distress develops. Accumulation of potassium may occur in renal impairment.
Side Effect
GI ulceration (sometimes with haemorrhage and perforation or with late formation of strictures) following the use of enteric-coated K chloride preparation; hyperkalaemia. Oral: Nausea, vomiting, diarrhoea and abdominal cramps. IV: Pain or phloebitis; cardiac toxicity.
Interaction
Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.
